CombiMatrix Corp. CBMXW 深 滬
等待開盤 11-17 09:30:00 美东时间
2.50
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 2.50
- 總市值 1840.00万
- 52周最高 3.00
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.62
- 委 比 0.00%
- 總股本 736.00万
- 歷史最高 3.00
- 量 比 0
- 振 幅 0.00%
- 歷史最低 0.62
- 每 手 1
- 風險率
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Biomea Fusion Announces Proposed Public Offering of Securities
Biomea Fusion, a clinical-stage diabetes and obesity company, has initiated an underwritten public offering of its common stock and warrants. The offering includes pre-funded warrants and common stock warrants, with underwriters having a 30-day option to buy up to an additional 15% of shares or warrants. The offering is subject to market conditions and regulatory filings. Jefferies is serving as the sole book-running manager. The securities are b...
10-06 20:18
Mainz Biomed Announces Registration of ColoAlert in the United Kingdom
Mainz Biomed's ColoAlert®, a non-invasive DNA-based colorectal cancer screening test, has been officially registered with the UK's MHRA and authorized for marketing. This milestone, achieved through a partnership with EDX Medical Group, aims to increase accessibility and participation in CRC screening, addressing the UK's fourth most common cancer. ColoAlert detects DNA biomarkers in stool samples, complementing existing screening programs and of...
09-02 12:01
Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA)
Biomea Fusion announced new data on icovamenib, an oral menin inhibitor, at ADA 2025. Preclinical studies show icovamenib enhances glycemic control and weight loss when combined with low-dose semaglutide, while preserving lean mass. It also rescues human myotube atrophy ex vivo. In the Phase II COVALENT-111 trial, icovamenib achieved a 1.0% placebo-adjusted HbA1c reduction and a 55% increase in C-peptide at Week 26, demonstrating durable effects ...
06-23 11:00
